Jump to content

BioGaia

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Apipattana (talk | contribs) at 05:42, 21 October 2023 (Adding the ISIN code of this company and the ticker symbol of this company listed on the Nasdaq Stockholm). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

BioGaia
Company typePublic (Aktiebolag)
Nasdaq Stockholm: BIOG B
ISINSE0017769995
IndustryProbiotics
Founded1990
HeadquartersStockholm, Sweden
Area served
Worldwide
Key people
Peter Rothschild
(President)
ProductsBioGaia ProTectis drops, BioGaia ProTectis tablets, BioGaia ProTectis D3 drops, BioGaia ProTectis ORS, BioGaia ProDentis lozenges
Websitehttp://www.biogaia.com

BioGaia is a Swedish biotechnology company that develops, markets and sells a range of probiotic products.[1][2][3] It has patented the use of several Lactobacillus reuteri strains and offers gut and immune health products containing L. reuteri Protectis (DSM 17938), one of the human L. reuteri strain and oral health products containing L. reuteri Prodentis, a blend of the L. reuteri strains DSM 17938 and ATCC PTA 5289.[citation needed] Products containing L. reuteri have been proven to be both effective and safe in several applications:[dubious – discuss] infant colic,[4][5] diarrhea prevention and mitigation in children,[6][7] eradication of H. pylori infection and reduction of side effects from standard H. pylori treatment,[8][9][10] amelioration of gingivitis,[11][12] and general illness prevention in children[13] and adults.[14] BioGaia was ranked 9th in the Top 30 Global Probiotic Food Ingredient Companies list by FoodTalks in 2021.[15] The BioGaia -B share is listed on the NASDAQ OMX Nordic Exchange.[citation needed]

History

BioGaia was founded in 1990 to develop and commercialize a new strain of L. reuteri. The company's research director Dr. Ivan Casas believed that newborn chickens consumed their mothers' feces, allowing the transfer of beneficial microorganisms from the mother to the sterile newborn bird. He believed that the same was true for humans.[16] It is generally accepted that newborn babies are sterile at birth and are very sensitive to pathogenic bacteria before they establish a microbial flora of their own.[17]

This flora should preferably come from their mother. Ivan believed that Lactobacillus reuteri is one of the bacteria that a mother should transfer to her offspring, whether a chicken, a human baby or any other mammal. He wanted to create probiotic products that would confirm this "Circle of Life”.[citation needed]

The first step involved analysis of breast milk from mothers in the United States, Sweden, Israel, South Africa, Denmark, Japan, Peru and South Korea. Approximately 14-15% of the samples contained L. reuteri.[18] In a separate study, Casas found that samples of breast milk collected from women in Andean villages in Peru also contained numerous strains of L. reuteri, which were subsequently isolated.[19]

One of these strains is still used in BioGaia’s probiotic products.[20][citation needed]

References

  1. ^ Reid, G (1999). "The scientific basis for probiotic strains of Lactobacillus". Applied and Environmental Microbiology. 65 (9): 3763–6. PMC 99697. PMID 10473372.
  2. ^ Klein, K; Stevens, R (2008). "The clinical use of probiotics for young children". The Journal of Family Health Care. 18 (2): 66–8. PMID 18512639.[unreliable medical source?]
  3. ^ Guandalini, S (2011). "Probiotics for prevention and treatment of diarrhea". Journal of Clinical Gastroenterology. 45 Suppl: S149–53. doi:10.1097/MCG.0b013e3182257e98. PMID 21992955.[unreliable medical source?]
  4. ^ Savino, F.; Pelle, E.; Palumeri, E.; Oggero, R.; Miniero, R. (2007). "Lactobacillus reuteri (American Type Culture Collection Strain 55730) Versus Simethicone in the Treatment of Infantile Colic: A Prospective Randomized Study". Pediatrics. 119 (1): 124–30. doi:10.1542/peds.2006-1222. PMID 17200238.
  5. ^ Savino, F.; Cordisco, L.; Tarasco, V.; Palumeri, E.; Calabrese, R.; Oggero, R.; Roos, S.; Matteuzzi, D. (2010). "Lactobacillus reuteri DSM 17938 in Infantile Colic: A Randomized, Double-Blind, Placebo-Controlled Trial". Pediatrics. 126 (3): e526–33. doi:10.1542/peds.2010-0433. PMID 20713478.[unreliable medical source?]
  6. ^ Ruiz-Palacios, Guillermo; Guerrero, M. Lourdes; Hilty, Milo; Dohnalek, Margaret; Newton, Pamela; Calva, Juan J.; Costigan, Tim; Tuz, Fernando; Arteaga, Fernando (1996). "Feeding of A Probiotic for the Prevention of Community-Acquired Diarrhea in Young Mexican Children". Pediatric Research. 39 (4): 184. doi:10.1203/00006450-199604001-01111.[unreliable medical source?]
  7. ^ Shornikova, Aino-Vieno; Casas, Ivan A.; Mykkänen, Hannu; Salo, Eeva; Vesikari, Timo (1997). "Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis". The Pediatric Infectious Disease Journal. 16 (12): 1103–7. doi:10.1097/00006454-199712000-00002. PMID 9427453.[unreliable medical source?]
  8. ^ Francavilla, R; Lionetti, E; Castellaneta, SP; Magistà, AM; Maurogiovanni, G; Bucci, N; De Canio, A; Indrio, F; et al. (2008). "Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: A pilot study". Helicobacter. 13 (2): 127–34. doi:10.1111/j.1523-5378.2008.00593.x. PMID 18321302.
  9. ^ Lionetti, E; Miniello, VL; Castellaneta, SP; Magistá, AM; De Canio, A; Maurogiovanni, G; Ierardi, E; Cavallo, L; Francavilla, R (2006). "Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: A randomized placebo controlled trial". Alimentary Pharmacology & Therapeutics. 24 (10): 1461–8. doi:10.1111/j.1365-2036.2006.03145.x. PMID 17032283.[unreliable medical source?]
  10. ^ Imase, K; Tanaka, A; Tokunaga, K; Sugano, H; Ishida, H; Takahashi, S (2007). "Lactobacillus reuteri tablets suppress Helicobacter pylori infection--a double-blind randomised placebo-controlled cross-over clinical study". Kansenshogaku Zasshi. 81 (4): 387–93. doi:10.11150/kansenshogakuzasshi1970.81.387. PMID 17695792.
  11. ^ Vivekananda, MR; Vandana, KL; Bhat, KG (2010). "Effect of the probiotic Lactobacilli reuteri (Prodentis) in the management of periodontal disease: A preliminary randomized clinical trial". Journal of Oral Microbiology. 2: 5344. doi:10.3402/jom.v2i0.5344. PMC 3084569. PMID 21523225.[unreliable medical source?]
  12. ^ Krasse, P; Carlsson, B; Dahl, C; Paulsson, A; Nilsson, A; Sinkiewicz, G (2006). "Decreased gum bleeding and reduced gingivitis by the probiotic Lactobacillus reuteri". Swedish Dental Journal. 30 (2): 55–60. PMID 16878680.[unreliable medical source?]
  13. ^ Weizman, Z; Asli, G; Alsheikh, A (2005). "Effect of a probiotic infant formula on infections in child care centers: Comparison of two probiotic agents". Pediatrics. 115 (1): 5–9. doi:10.1542/peds.2004-1815. PMID 15629974.[unreliable medical source?]
  14. ^ Tubelius, P; Stan, V; Zachrisson, A (2005). "Increasing work-place healthiness with the probiotic Lactobacillus reuteri: A randomised, double-blind placebo-controlled study". Environmental Health. 4: 25. doi:10.1186/1476-069X-4-25. PMC 1298318. PMID 16274475.{{cite journal}}: CS1 maint: unflagged free DOI (link)[unreliable medical source?]
  15. ^ Zhao, Viola (2021-04-20). "2021年全球食用益生菌原料企业30强". www.foodtalks.cn (in Chinese). Archived from the original on 2022-01-17. Retrieved 2022-01-21.
  16. ^ Ivan a. Casas, Walter j. Dobrogosz (2000). "Validation of the Probiotic Concept:Lactobacillus reuteriConfers Broad-spectrum Protection against Disease in Humans and Animals". Microbial Ecology in Health and Disease. 12 (4): 247–85. doi:10.1080/08910600050216246-1.[unreliable medical source?]
  17. ^ Fanaro, S; Chierici, R; Guerrini, P; Vigi, V (2003). "Intestinal microflora in early infancy: Composition and development". Acta Paediatrica. 91 (441): 48–55. doi:10.1111/j.1651-2227.2003.tb00646.x. PMID 14599042.[unreliable medical source?]
  18. ^ Sinkiewicz, Gabriela; Ljunggren, Lennart (2008). "Occurrence ofLactobacillus reuteriin human breast milk". Microbial Ecology in Health and Disease. 20 (3): 122–126. doi:10.1080/08910600802341007.[unreliable medical source?]
  19. ^ Talarico, TL; Casas, IA; Chung, TC; Dobrogosz, WJ (1988). "Production and isolation of reuterin, a growth inhibitor produced by Lactobacillus reuteri". Antimicrobial Agents and Chemotherapy. 32 (12): 1854–8. doi:10.1128/aac.32.12.1854. PMC 176032. PMID 3245697.[unreliable medical source?]
  20. ^ "Biogaia Probiotics - BioGaia's history". www.biogaia.com. Retrieved 2018-02-22.
Retrieved from "https://en.wikipedia.org/w/index.php?title=BioGaia&oldid=1181153869"